Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Non-Current Liabilities (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Total Non-Current Liabilities for 12 consecutive years, with $436.5 million as the latest value for Q1 2026.

  • For Q1 2026, Total Non-Current Liabilities rose 1.29% year-over-year to $436.5 million; the TTM value through Mar 2026 reached $436.5 million, up 1.29%, while the annual FY2025 figure was $422.5 million, 3.53% down from the prior year.
  • Total Non-Current Liabilities hit $436.5 million in Q1 2026 for Cartesian Therapeutics, up from $422.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $454.6 million in Q3 2024 and bottomed at $32.6 million in Q3 2023.
  • Average Total Non-Current Liabilities over 5 years is $278.0 million, with a median of $407.7 million recorded in 2025.
  • Year-over-year, Total Non-Current Liabilities crashed 58.94% in 2022 and then soared 1293.77% in 2024.
  • Cartesian Therapeutics' Total Non-Current Liabilities stood at $52.9 million in 2022, then soared by 728.24% to $438.3 million in 2023, then dropped by 0.07% to $438.0 million in 2024, then dropped by 3.53% to $422.5 million in 2025, then grew by 3.3% to $436.5 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $436.5 million, $422.5 million, and $407.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.